Obana M, Irimajiri S, Tomizawa I, Takizawa Y, Sakamoto Y, Nitta Y, Tsunoda T, Fukuda H, Yamaguchi T, Masuda G
Department of Internal Medicine, Kawasaki Municipal Hospital, Kanagawa.
Kansenshogaku Zasshi. 1995 Sep;69(9):991-1006. doi: 10.11150/kansenshogakuzasshi1970.69.991.
The efficacy, safety and usefulness of balofloxacin (BLFX) for patients with acute infectious enteritis and the carriers mainly shigellosis, were investigated. The drug was administered at a daily dose of 200 mg twice a day for 3 days to patients with cholera, 7 days to patients with Salmonella enteritis and 5 days to patients with other conditions of infectious enteritis including shigellosis; 1. The efficacy was analyzed in 89 of the 135 patients who received the administration (43 patients with shigellosis, 14 with Salmonella enteritis, 8 with enteropathogenic/ enterotoxigenic Escherichia coli enteritis, 3 with cholera, 7 with enteritis with other pathogenic bacteria, 6 with polymicrobial infectious enteritis and 8 with acute enteritis that was pathogen-negative). 2. In patients bearing symptoms and who thus could be analyzed for drug efficacy, the drug was markedly effective or effective 50/52 (96.2%). 3. Bacteriologically, the drug was effective for Shigella spp. in 41 (100%) of 41, Salmonella spp. in 12 (85.7%) of 14, and enteropathogenic/enterotoxigenic Escherichia coli in 8 of 8 cases. 4. Adverse effects were seen in 5/133 patients (3.8%) receiving the drug, including two cases of skin eruption, one of the numbness of the hands, one of oral aphtha, and one of nausea. In patients for whom laboratory findings were available, 20/115 (17.4%) showed abnormalities, mainly elevations of GOT and/or GPT, but these were slight. 5. In terms of subjective reports of usefulness, 51/82 (62.2%) were markedly satisfied, and 73/82 (89.0%) were either satisfied or markedly satisfied. 6. The influence of administration of BLFX on fecal concentration and intestinal microbial flora was investigated in 2 patients with acute infectious enteritis. Results approximately equivalent to such flora levels in healthy subjects were obtained. These results suggest that BLFX is highly useful for infectious enteritis such as that caused by shigellosis.
研究了巴洛沙星(BLFX)对急性感染性肠炎患者以及以志贺菌病为主的带菌者的疗效、安全性和实用性。霍乱患者每天服用200mg,分两次服用,共3天;沙门氏菌肠炎患者服用7天;其他包括志贺菌病在内的感染性肠炎患者服用5天。1. 在135例接受给药的患者中,对89例进行了疗效分析(43例志贺菌病患者、14例沙门氏菌肠炎患者、8例致病性/产毒性大肠杆菌肠炎患者、3例霍乱患者、7例其他病原菌引起的肠炎患者、6例混合菌感染性肠炎患者和8例病原菌阴性的急性肠炎患者)。2. 在有症状且可分析药物疗效的患者中,该药物显效或有效者为50/52(96.2%)。3. 从细菌学角度看,该药物对41例志贺菌属中的41例(100%)、14例沙门氏菌属中的12例(85.7%)以及8例致病性/产毒性大肠杆菌均有效。4. 在133例接受该药物治疗的患者中,有5例(3.8%)出现不良反应,包括2例皮疹、1例手部麻木、1例口腔溃疡和1例恶心。在有实验室检查结果的患者中,20/115(17.4%)出现异常,主要是谷草转氨酶和/或谷丙转氨酶升高,但程度较轻。5. 就主观有用性报告而言,51/82(62.2%)患者非常满意,73/82(89.0%)患者满意或非常满意。6. 对2例急性感染性肠炎患者研究了BLFX给药对粪便浓度和肠道微生物菌群的影响。结果获得了与健康受试者的菌群水平大致相当的结果。这些结果表明,BLFX对志贺菌病等感染性肠炎非常有用。